BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma C, Yan K, Wang Z, Zhang Q, Gao L, Xu T, Sai J, Cheng F, Du Y. The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis. Bioengineered 2021;12:2187-202. [PMID: 34096467 DOI: 10.1080/21655979.2021.1933302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Yoshikawa S, Taniguchi K, Sawamura H, Ikeda Y, Asai T, Tsuji A, Matsuda S. Metabolic Associated Fatty Liver Disease as a Risk Factor for the Development of Central Nervous System Disorders. Livers 2023;3:21-32. [DOI: 10.3390/livers3010002] [Reference Citation Analysis]
2 Shatta MA, El-derany MO, Gibriel AA, El-mesallamy HO. Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro. Mol Cell Biochem 2022. [DOI: 10.1007/s11010-022-04619-6] [Reference Citation Analysis]
3 Lan Y, Lu Y, Li J, Hu S, Chen S, Wang Y, Yuan X, Liu H, Wang X, Wu S, Wang L. Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in China. Hepatol Commun 2022;6:3393-405. [PMID: 36281973 DOI: 10.1002/hep4.2081] [Reference Citation Analysis]
4 Zhu Y, Yang H, Liang S, Zhang H, Mo Y, Rao S, Zhang Y, Zhang Z, Wang W, Yang W. Higher Adherence to Healthy Lifestyle Score Is Associated with Lower Odds of Non-Alcoholic Fatty Liver Disease. Nutrients 2022;14:4462. [DOI: 10.3390/nu14214462] [Reference Citation Analysis]
5 Ji J, Feng M, Huang Y, Niu X. Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro. Bioengineered 2022;13:5091-102. [PMID: 35164657 DOI: 10.1080/21655979.2022.2036902] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]